To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Bicalutamide
Bicalutamide (marketed as Casodex®, Cosudex®, Calutide®, Kalumid®) is an oral non-steroidal anti-androgen for prostate cancer. It was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease. It is marketed by AstraZeneca with the brand names Casodex and Cosudex. Bicalutamide is recommended 50 mg once daily in combination with an LHRH analogue or surgical castration. Additional recommended knowledge
DescriptionBicalutamide is an oral non-steroidal anti-androgen with the empirical formula C18H14N2O4F4S and is an off-white powder that is practically insoluble in water. Indications and useFor the treatment of stage D2 metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone analogue or as a monotherapy. Has been used in clinical trials for ovarian cancer. Contraindications and precautionsBicalutamide is contra-indicated in females and children and must not be given to any patient who has shown a hypersensitivity reaction to its use. Adverse reactionsAdverse reactions include reproductive system and breast disorders, breast tenderness, gynaecomastia, hot flushes, gastrointestinal disorders, diarrhoea, nausea, hepatic changes (elevated levels of transaminases, jaundice), asthenia and pruritus. |
|||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bicalutamide". A list of authors is available in Wikipedia. |